文献速递腹部技术与安全USMR

代谢功能障碍相关脂肪性肝病命名、诊断与管理的当前更新:放射科医生视角

Current Update on Nomenclature, Diagnosis, and Management of Metabolic Dysfunction-associated Steatotic Liver Disease: Radiologists' Perspective.
PubMed 文献 · Radiographics · 2025-01-01

本文综述代谢功能障碍相关脂肪性肝病(MASLD)取代非酒精性脂肪性肝病(NAFLD)的新命名与定义,介绍2023年美国肝病研究学会(AASLD)实践指导及基于血液和影像的无创评估指南,并总结超声与MRI技术进展使放射科医生在早期检测、准确评估和监测中发挥关键作用,以及resmetirom获批用于治疗非肝硬化伴中重度肝纤维化的成人MASLD患者。

要点

  • MASLD已取代NAFLD,MASH取代NASH,新命名经全球多学会德尔菲共识批准。
  • 2023年AASLD实践指导纳入诊断与管理变化,并发布基于血液和影像的无创肝纤维化与脂肪变评估指南。
  • 超声与MRI技术进步使放射科医生在MASLD早期检测、准确评估和监测中发挥关键作用。

核心结论

  • MASLD是NAFLD的新名称,随着肥胖和代谢综合征患病率增加,已成为重要全球健康问题;近5年对发病机制和自然史的理解取得重大突破,影像学评估正从侵入性检查向先进影像诊断转变,放射科医生在MASLD管理和预后判断中起关键作用。

研究设计与样本

  • 综述类文章,检索范围与纳入文献原文未报告;文章总结新命名与定义、2023年AASLD实践指导及基于血液和影像的无创肝病评估指南,并综述超声与MRI技术进展及resmetirom治疗进展。

临床应用与阅片要点

  • 作者指出,超声和MRI技术的最新进展使放射科医生能够在MASLD的早期检测、准确评估和监测中发挥关键作用,从而及时干预和改变生活方式;文章旨在为放射科医生提供参考。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the new name for nonalcoholic fatty liver disease (NAFLD). MASLD continues to be a significant global health care problem, commensurate with the increased prevalence of obesity and metabolic syndrome. The study of MASLD has intensified over the past 5 years, with major breakthroughs in understanding the pathogenesis and natural history. The American Association for the Study of Liver Diseases (AASLD) published practice guidance in 2023 to incorporate changes in diagnosis and management. A new nomenclature for MASLD, with updated definitions, has been approved through a global multisociety-led Delphi consensus to replace NAFLD with MASLD and nonalcoholic steatohepatitis (NASH) with metabolic dysfunction-associated steatohepatitis (MASH). AASLD practice guidelines on blood-based and imaging-based noninvasive liver disease assessments of hepatic fibrosis and steatosis have also been recently published. The latest advances in US and MRI techniques have allowed radiologists to play a pivotal role in early detection, accurate assessment, and monitoring of diseases, thus enabling timely intervention and lifestyle changes. Resmetirom has recently been approved for treating noncirrhotic adult patients with MASLD and moderate to severe hepatic fibrosis, along with diet and exercise. The authors review the role of imaging in the new guidelines as the current evaluation of MASLD transitions from invasive tests to advanced imaging-based diagnostics. The article will serve as a reference for radiologists, who play a critical role in managing and prognosticating MASLD. ©RSNA, 2025 Supplemental material is available for this article.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Osta EG, Saenz F, Jaganathan S, et al. Current Update on Nomenclature, Diagnosis, and Management of Metabolic Dysfunction-associated Steatotic Liver Disease: Radiologists' Perspective. Radiographics. 2025. PMID: 41231713. doi:10.1148/rg.240221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。